Personalized medicine and chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 23, Issue 3, 2017, Pages 241-246

  Wouters, E F M ^a,b   Wouters, B B R A F ^c   Augustin, I M L ^b   Franssen, F M E ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Centre of Expertise for Chronic Organ Failure   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Personalized medicine; Precision medicine; Pulmonary rehabilitation

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; ROFLUMILAST; TUMOR NECROSIS FACTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OUTCOME; DISEASE SEVERITY; HUMAN; LUNG EMPHYSEMA; PERSONALIZED MEDICINE; PHENOTYPE; PROGNOSIS; PULMONARY REHABILITATION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPIROMETRY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; HUMANS; PRECISION MEDICINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 85014201184     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000377     Document Type: Review

References (47)

1. Speizer FE, Ware JH. Exploring different phenotypes of COPD. N Engl J Med 2015; 373:185-186.
2. GOLD. Global strategy for the diagnosis, management and prevention of COPD (updated 2016). http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. [Accessed 4 January 2017]
3. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182:693-718.
4. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1:1645-1648.
5. Reilly JJ. COPD and declining FEV1: time to divide and conquer? N Engl J Med 2008; 359:1616-1618.
6. Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015; 175:1539-1549.
7. Agusti A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10 (Suppl):S125-S130.
8. Plsek PE, Wilson T. Complexity, leadership, and management in healthcare organisations. BMJ 2001; 323:746-749.
9. Labaki WW, Martinez CH, Han MK. COPD in 2016: some answers, more questions. Lancet Respir Med 2016; 4:941-943.
10. Jameson JL, Longo DL. Precision medicine: personalized, problematic, and promising. N Engl J Med 2015; 372:2229-2234.
11. Xie H, Frueh F. Pharmacogenomics steps toward personalized medicine. Per Med 2005; 2:325-337.
12. Scholz N. Personalised medicine. The right treatment for the right person at the right time. 2015, http://www.europarl.europa.eu/RegData/etudes/BRIE/2015/569009/EPRS-BRI%282015%29569009-EN.pdf. [Accessed 4 January 2017]
13. Wilson T, Holt T, Greenhalgh T. Complexity science: complexity and clinical care. BMJ 2001; 323:685-688.
14. Greenhalgh T. Narrative based medicine: narrative based medicine in an evidence based world. BMJ 1999; 318:323-325.
15. Cox K. Clinical practice is not applied scientific method. Aust N Z J Surg 1995; 65:553-557.
16. Nordstrom K, Juth N, Kjellstrom S, et al., Food4Me project. Values at stake: autonomy, responsibility, and trustworthiness in relation to genetic testing and personalized nutrition advice. Genes Nutr 2013; 8:365-372.
17. Huber M, Knottnerus JA, Green L, et al. How should we define health? BMJ 2011; 343:d4163.
18. WHO. Constitution of the World Health Organization. 2006, http://www.who.int/governance/eb/who-constitution-en.pdf. [Accessed 4 January 2017]
19. Jadad AR, O'Grady L. How should health be defined? BMJ 2008; 337: a2900.
20. Snyderman R. Personalized healthcare: from theory to practice. Biotechnol J 2012; 7:973-979.
21. Lusuardi M, Ambrosino N, Donner C. Definition and rationale for pulmonary rehabilitation. In: Donner C, Ambrosino N, Goldstein R, editors. Pulmonary rehabilitation. Arnold London; 2005. pp. 3-8.
22. Fishman AP. Pulmonary rehabilitation research. Am J Respir Crit Care Med 1994; 149:825-833.
23. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188:e13-e64.
24. Augustin I, Spruit M, Franssen F, Wouters E. Understanding complexity of chronic noncommunicable diseases: an integrated approach for personalized management of patients with COPD. 2015; https://www.jscimedcentral.-com/Pulmonology/pulmonology-3-1034.pdf:1-9. [Accessed 4 January 2017]
25. Spruit MA, Augustin IM, Vanfleteren LE, et al. Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. Eur Respir J 2015; 46:1625-1635.
26. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68:687-690.
27. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47:410-419.
28. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182:598-604.
29. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012.
30. Burgel PR, Paillasseur JL, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36:531-539.
31. Burgel PR, Paillasseur JL, Peene B, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 2012; 7:e51048.
32. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:728-735.
33. Barabasi AL. Network medicine: from obesity to the 'diseasome'. N Engl J Med 2007; 357:404-407.
34. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365:2225-2236.
35. Teschler H. Long-term experience in the treatment of alpha1-antitrypsin deficiency: 25 years of augmentation therapy. Eur Respir Rev 2015; 24:46-51.
36. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33:1345-1353.
37. Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11:136.
38. Chapman K, Burdon J, Piitulainen E, et al. IV alpha-1 antitrypsin (a1aT) preserves lung density in homozygous alpha-1 antitrypsin deficiency (a1atd): a randomized, placebo-controlled trial. Am J Respir Crit Care Med 2013; 187:A6069.
39. FeldmannM, Brennan FM, Foxwell BM, et al. Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005; 25 (Suppl):26-28.
40. van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:465-469.
41. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:926-934.
42. Singh D. P38 inhibition in COPD; cautious optimism. Thorax 2013; 68:705-706.
43. MacNee W, Allan RJ, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013; 68:738-745.
44. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52:416-424.
45. Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 191:1001-1011.
46. Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med 2016; 194:559-567.
47. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012; 29:613-624.